About Centre for Pharmacoepidemiology

Denna sida på svenska

Sweden has through its healthcare registers, biobanks together with high levels of epidemiological, pharmacological and other expertise a unique opportunity to meet these demands. Health care providers, regulatory agencies and the pharmaceutical industry have identified drug safety, and rational drug use together with use of genetics and biomarkers as the most important issues for pharmacoepidemiological research. CPE has established collaboration with national and international research groups and the centre is part of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and the Nordic network for Pharmacoepidemiology (NorPEN). CPE is working in close collaboration with researchers at the Unit for Clinical Epidemiology at the Department of Medicine and is linked with other groups within epidemiology and pharmacology at Karolinska Institutet.

Head of Centre

Center director

Helle Kieler

Phone: +46-(0)8-517 706 29
Organizational unit: Centre for Pharmacoepidemiology / H Kieler
E-mail: Helle.Kieler@ki.se

Prioritized research areas:

Cancer and drugs 

Cardiovascular diseases and drugs 

Chronic diseases and biologics

CNS and drugs

Reproductive pharmacoepidemiology